InMed’s Year-End Correspondence To Shareholders Focuses On Its Accomplishments And A Bullish Future Jan 6, 2022
Revive Therapeutics To Expedite Patient Enrollments For Phase 3 COVID Oral Therapeutic Trial Jan 5, 2022
